The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Ponatinib-Global Market Insights and Sales Trends 2025
Synopsis
Ponatinib Drugs is an oral drug developed by ARIAD Pharmaceuticalsfor the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia(ALL).
The global Ponatinib market size is expected to reach US$ 902.8 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Ponatinib in various end use industries. The expanding demands from the CML and ALL, are propelling Ponatinib market. 45mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 15mg segment is estimated at % CAGR for the next seven-year period.
For many patients with CML or Ph+ ALL, ponatinib became a long-term treatment to manage their condition effectively. This sustained demand was driven by the need for ongoing therapy to control cancer progression.
Ongoing clinical trials and research exploring the use of ponatinib in different settings, combinations, or other types of cancer may have increased interest and demand for the drug.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Ponatinib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Ponatinib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Ponatinib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Ponatinib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Ponatinib covered in this report include ARIAD Pharmaceuticals. etc.
The global Ponatinib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
ARIAD Pharmaceuticals
Global Ponatinib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Ponatinib market, Segment by Type:
45mg
15mg
Global Ponatinib market, by Application
CML
ALL
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Ponatinib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Ponatinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Ponatinib Drugs is an oral drug developed by ARIAD Pharmaceuticalsfor the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia(ALL).
The global Ponatinib market size is expected to reach US$ 902.8 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Ponatinib in various end use industries. The expanding demands from the CML and ALL, are propelling Ponatinib market. 45mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 15mg segment is estimated at % CAGR for the next seven-year period.
For many patients with CML or Ph+ ALL, ponatinib became a long-term treatment to manage their condition effectively. This sustained demand was driven by the need for ongoing therapy to control cancer progression.
Ongoing clinical trials and research exploring the use of ponatinib in different settings, combinations, or other types of cancer may have increased interest and demand for the drug.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Ponatinib, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Ponatinib market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Ponatinib market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Ponatinib sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Ponatinib covered in this report include ARIAD Pharmaceuticals. etc.
The global Ponatinib market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
ARIAD Pharmaceuticals
Global Ponatinib market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Ponatinib market, Segment by Type:
45mg
15mg
Global Ponatinib market, by Application
CML
ALL
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Ponatinib manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Ponatinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Ponatinib Market Overview
1.1 Ponatinib Product Overview
1.2 Ponatinib Market Segment by Type
1.2.1 45mg
1.2.2 15mg
1.3 Global Ponatinib Market Size by Type
1.3.1 Global Ponatinib Market Size Overview by Type (2018-2029)
1.3.2 Global Ponatinib Historic Market Size Review by Type (2018-2023)
1.3.3 Global Ponatinib Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Ponatinib Sales Breakdown by Type (2018-2023)
1.4.2 Europe Ponatinib Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Ponatinib Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Ponatinib Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Ponatinib Sales Breakdown by Type (2018-2023)
2 Global Ponatinib Market Competition by Company
2.1 Global Top Players by Ponatinib Sales (2018-2023)
2.2 Global Top Players by Ponatinib Revenue (2018-2023)
2.3 Global Top Players by Ponatinib Price (2018-2023)
2.4 Global Top Manufacturers Ponatinib Manufacturing Base Distribution, Sales Area, Product Type
2.5 Ponatinib Market Competitive Situation and Trends
2.5.1 Ponatinib Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Ponatinib Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Ponatinib as of 2022)
2.7 Date of Key Manufacturers Enter into Ponatinib Market
2.8 Key Manufacturers Ponatinib Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Ponatinib Status and Outlook by Region
3.1 Global Ponatinib Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Ponatinib Historic Market Size by Region
3.2.1 Global Ponatinib Sales in Volume by Region (2018-2023)
3.2.2 Global Ponatinib Sales in Value by Region (2018-2023)
3.2.3 Global Ponatinib Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Ponatinib Forecasted Market Size by Region
3.3.1 Global Ponatinib Sales in Volume by Region (2024-2029)
3.3.2 Global Ponatinib Sales in Value by Region (2024-2029)
3.3.3 Global Ponatinib Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Ponatinib by Application
4.1 Ponatinib Market Segment by Application
4.1.1 CML
4.1.2 ALL
4.2 Global Ponatinib Market Size by Application
4.2.1 Global Ponatinib Market Size Overview by Application (2018-2029)
4.2.2 Global Ponatinib Historic Market Size Review by Application (2018-2023)
4.2.3 Global Ponatinib Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Ponatinib Sales Breakdown by Application (2018-2023)
4.3.2 Europe Ponatinib Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Ponatinib Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Ponatinib Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Ponatinib Sales Breakdown by Application (2018-2023)
5 North America Ponatinib by Country
5.1 North America Ponatinib Historic Market Size by Country
5.1.1 North America Ponatinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Ponatinib Sales in Volume by Country (2018-2023)
5.1.3 North America Ponatinib Sales in Value by Country (2018-2023)
5.2 North America Ponatinib Forecasted Market Size by Country
5.2.1 North America Ponatinib Sales in Volume by Country (2024-2029)
5.2.2 North America Ponatinib Sales in Value by Country (2024-2029)
6 Europe Ponatinib by Country
6.1 Europe Ponatinib Historic Market Size by Country
6.1.1 Europe Ponatinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Ponatinib Sales in Volume by Country (2018-2023)
6.1.3 Europe Ponatinib Sales in Value by Country (2018-2023)
6.2 Europe Ponatinib Forecasted Market Size by Country
6.2.1 Europe Ponatinib Sales in Volume by Country (2024-2029)
6.2.2 Europe Ponatinib Sales in Value by Country (2024-2029)
7 Asia-Pacific Ponatinib by Region
7.1 Asia-Pacific Ponatinib Historic Market Size by Region
7.1.1 Asia-Pacific Ponatinib Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Ponatinib Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Ponatinib Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Ponatinib Forecasted Market Size by Region
7.2.1 Asia-Pacific Ponatinib Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Ponatinib Sales in Value by Region (2024-2029)
8 Latin America Ponatinib by Country
8.1 Latin America Ponatinib Historic Market Size by Country
8.1.1 Latin America Ponatinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Ponatinib Sales in Volume by Country (2018-2023)
8.1.3 Latin America Ponatinib Sales in Value by Country (2018-2023)
8.2 Latin America Ponatinib Forecasted Market Size by Country
8.2.1 Latin America Ponatinib Sales in Volume by Country (2024-2029)
8.2.2 Latin America Ponatinib Sales in Value by Country (2024-2029)
9 Middle East and Africa Ponatinib by Country
9.1 Middle East and Africa Ponatinib Historic Market Size by Country
9.1.1 Middle East and Africa Ponatinib Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Ponatinib Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Ponatinib Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Ponatinib Forecasted Market Size by Country
9.2.1 Middle East and Africa Ponatinib Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Ponatinib Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 ARIAD Pharmaceuticals
10.1.1 ARIAD Pharmaceuticals Company Information
10.1.2 ARIAD Pharmaceuticals Introduction and Business Overview
10.1.3 ARIAD Pharmaceuticals Ponatinib Sales, Revenue and Gross Margin (2018-2023)
10.1.4 ARIAD Pharmaceuticals Ponatinib Products Offered
10.1.5 ARIAD Pharmaceuticals Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Ponatinib Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Ponatinib Industrial Chain Analysis
11.4 Ponatinib Market Dynamics
11.4.1 Ponatinib Industry Trends
11.4.2 Ponatinib Market Drivers
11.4.3 Ponatinib Market Challenges
11.4.4 Ponatinib Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Ponatinib Distributors
12.3 Ponatinib Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
